Literature DB >> 16467198

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Michael R Betts1, Martha C Nason, Sadie M West, Stephen C De Rosa, Stephen A Migueles, Jonathan Abraham, Michael M Lederman, Jose M Benito, Paul A Goepfert, Mark Connors, Mario Roederer, Richard A Koup.   

Abstract

Establishing a CD8(+) T cell-mediated immune correlate of protection in HIV disease is crucial to the development of vaccines designed to generate cell-mediated immunity. Historically, neither the quantity nor breadth of the HIV-specific CD8(+) T-cell response has correlated conclusively with protection. Here, we assess the quality of the HIV-specific CD8(+) T-cell response by measuring 5 CD8(+) T-cell functions (degranulation, IFN-gamma, MIP-1beta, TNF-alpha, and IL-2) simultaneously in chronically HIV-infected individuals and elite nonprogressors. We find that the functional profile of HIV-specific CD8(+) T cells in progressors is limited compared to that of nonprogressors, who consistently maintain highly functional CD8(+) T cells. This limited functionality is independent of HLA type and T-cell memory phenotype, is HIV-specific rather than generalized, and is not effectively restored by therapeutic intervention. Whereas the total HIV-specific CD8(+) T-cell frequency did not correlate with viral load, the frequency and proportion of the HIV-specific T-cell response with highest functionality inversely correlated with viral load in the progressors. Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467198      PMCID: PMC1895811          DOI: 10.1182/blood-2005-12-4818

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors.

Authors:  J C Gea-Banacloche; S A Migueles; L Martino; W L Shupert; A C McNeil; M S Sabbaghian; L Ehler; C Prussin; R Stevens; L Lambert; J Altman; C W Hallahan; J C de Quiros; M Connors
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.

Authors:  C J Pitcher; C Quittner; D M Peterson; M Connors; R A Koup; V C Maino; L J Picker
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Authors:  Simone C Zimmerli; Alexandre Harari; Cristina Cellerai; Florence Vallelian; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-04       Impact factor: 11.205

4.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

5.  Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.

Authors:  S Fleury; G P Rizzardi; A Chapuis; G Tambussi; C Knabenhans; E Simeoni; J Y Meuwly; J M Corpataux; A Lazzarin; F Miedema; G Pantaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

7.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

9.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

10.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

View more
  963 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Authors:  Olusimidele T Akinsiku; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

4.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Authors:  María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

5.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

6.  Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.

Authors:  Alexandre Harari; Felicitas Bellutti Enders; Cristina Cellerai; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Authors:  Mathilde Allard; Barbara Couturaud; Laura Carretero-Iglesia; Minh Ngoc Duong; Julien Schmidt; Gwennaëlle C Monnot; Pedro Romero; Daniel E Speiser; Michael Hebeisen; Nathalie Rufer
Journal:  JCI Insight       Date:  2017-07-20

8.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

9.  A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.

Authors:  Hongmei Kong; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

10.  HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine.

Authors:  Nazma Mansoor; Thomas J Scriba; Marwou de Kock; Michele Tameris; Brian Abel; Alana Keyser; Francesca Little; Andreia Soares; Sebastian Gelderbloem; Silvia Mlenjeni; Lea Denation; Anthony Hawkridge; W Henry Boom; Gilla Kaplan; Gregory D Hussey; Willem A Hanekom
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.